FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081987637> ?p ?o ?g. }

• W2081987637 endingPage "1028" @default.
• W2081987637 startingPage "1021" @default.
• W2081987637 abstract "This prospective open-label pilot study evaluated the effectiveness and safety of adalimumab and the relationship to antibodies against infliximab (IFX) in adult patients with active rheumatoid arthritis (RA) who had been treated previously with IFX and experienced treatment failure owing to lack or loss of response or intolerance. Patients self-administered adalimumab 40 mg subcutaneously every other week for 16 weeks, followed by maintenance therapy for up to Week 56. Measures of effectiveness included American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) response criteria, 28-joint Disease Activity Score, and the Health Assessment Questionnaire Disability Index. Serum IFX concentrations, human antichimeric antibody against IFX (HACA), adalimumab serum concentrations, antiadalimumab antibody, and safety also were assessed. Of the 41 enrolled patients, 37 completed 16 weeks and 30 completed 56 weeks of treatment. Patients experienced clinically meaningful improvements in all measures of RA activity, with greater response rates observed for patients who had experienced loss of initial response to or intolerance of IFX. At Week 16, 46% of patients achieved an ACR20 and 28% achieved an ACR50; 61% achieved an at least moderate and 17% achieved a good EULAR response. Clinical benefit was maintained through Week 56 in all effectiveness parameters. Baseline HACA status did not significantly impact effectiveness. No new safety signals were observed; neither former IFX intolerance status nor baseline HACA status had a clinically relevant impact on adverse event frequency or severity. Adalimumab was effective and well-tolerated in patients with RA who previously failed IFX therapy, irrespective of reason for discontinuation and of HACA status." @default.
• W2081987637 created "2016-06-24" @default.
• W2081987637 creator A5016157822 @default.
• W2081987637 creator A5019162794 @default.
• W2081987637 creator A5048909196 @default.
• W2081987637 creator A5052424289 @default.
• W2081987637 creator A5066746944 @default.
• W2081987637 creator A5074767050 @default.
• W2081987637 creator A5076851275 @default.
• W2081987637 creator A5079625006 @default.
• W2081987637 creator A5087825846 @default.
• W2081987637 date "2008-03-19" @default.
• W2081987637 modified "2023-10-18" @default.
• W2081987637 title "An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status" @default.
• W2081987637 cites W1980521490 @default.
• W2081987637 cites W1996389186 @default.
• W2081987637 cites W1996437423 @default.
• W2081987637 cites W1999777294 @default.
• W2081987637 cites W2014709373 @default.
• W2081987637 cites W2017883234 @default.
• W2081987637 cites W2036977213 @default.
• W2081987637 cites W2046628605 @default.
• W2081987637 cites W2112966993 @default.
• W2081987637 cites W2118704147 @default.
• W2081987637 cites W2119046820 @default.
• W2081987637 cites W2122265491 @default.
• W2081987637 cites W2132624379 @default.
• W2081987637 cites W2133028044 @default.
• W2081987637 cites W2133541603 @default.
• W2081987637 cites W2138410868 @default.
• W2081987637 cites W2152721471 @default.
• W2081987637 cites W2157770246 @default.
• W2081987637 cites W2163204760 @default.
• W2081987637 doi "https://doi.org/10.1007/s10067-008-0866-4" @default.
• W2081987637 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2468311" @default.
• W2081987637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18350329" @default.
• W2081987637 hasPublicationYear "2008" @default.
• W2081987637 type Work @default.
• W2081987637 sameAs 2081987637 @default.
• W2081987637 citedByCount "79" @default.
• W2081987637 countsByYear W20819876372012 @default.
• W2081987637 countsByYear W20819876372013 @default.
• W2081987637 countsByYear W20819876372014 @default.
• W2081987637 countsByYear W20819876372015 @default.
• W2081987637 countsByYear W20819876372016 @default.
• W2081987637 countsByYear W20819876372017 @default.
• W2081987637 countsByYear W20819876372018 @default.
• W2081987637 countsByYear W20819876372019 @default.
• W2081987637 countsByYear W20819876372020 @default.
• W2081987637 countsByYear W20819876372021 @default.
• W2081987637 countsByYear W20819876372022 @default.
• W2081987637 crossrefType "journal-article" @default.
• W2081987637 hasAuthorship W2081987637A5016157822 @default.
• W2081987637 hasAuthorship W2081987637A5019162794 @default.
• W2081987637 hasAuthorship W2081987637A5048909196 @default.
• W2081987637 hasAuthorship W2081987637A5052424289 @default.
• W2081987637 hasAuthorship W2081987637A5066746944 @default.
• W2081987637 hasAuthorship W2081987637A5074767050 @default.
• W2081987637 hasAuthorship W2081987637A5076851275 @default.
• W2081987637 hasAuthorship W2081987637A5079625006 @default.
• W2081987637 hasAuthorship W2081987637A5087825846 @default.
• W2081987637 hasBestOaLocation W20819876371 @default.
• W2081987637 hasConcept C126322002 @default.
• W2081987637 hasConcept C1862650 @default.
• W2081987637 hasConcept C197934379 @default.
• W2081987637 hasConcept C198451711 @default.
• W2081987637 hasConcept C2777138892 @default.
• W2081987637 hasConcept C2777489490 @default.
• W2081987637 hasConcept C2777575956 @default.
• W2081987637 hasConcept C2779134260 @default.
• W2081987637 hasConcept C2780132546 @default.
• W2081987637 hasConcept C71924100 @default.
• W2081987637 hasConceptScore W2081987637C126322002 @default.
• W2081987637 hasConceptScore W2081987637C1862650 @default.
• W2081987637 hasConceptScore W2081987637C197934379 @default.
• W2081987637 hasConceptScore W2081987637C198451711 @default.
• W2081987637 hasConceptScore W2081987637C2777138892 @default.
• W2081987637 hasConceptScore W2081987637C2777489490 @default.
• W2081987637 hasConceptScore W2081987637C2777575956 @default.
• W2081987637 hasConceptScore W2081987637C2779134260 @default.
• W2081987637 hasConceptScore W2081987637C2780132546 @default.
• W2081987637 hasConceptScore W2081987637C71924100 @default.
• W2081987637 hasIssue "8" @default.
• W2081987637 hasLocation W20819876371 @default.
• W2081987637 hasLocation W20819876372 @default.
• W2081987637 hasLocation W20819876373 @default.
• W2081987637 hasLocation W20819876374 @default.
• W2081987637 hasOpenAccess W2081987637 @default.
• W2081987637 hasPrimaryLocation W20819876371 @default.
• W2081987637 hasRelatedWork W1555548379 @default.
• W2081987637 hasRelatedWork W1973470095 @default.
• W2081987637 hasRelatedWork W1976481621 @default.
• W2081987637 hasRelatedWork W1993992685 @default.
• W2081987637 hasRelatedWork W2081987637 @default.
• W2081987637 hasRelatedWork W2328313486 @default.
• W2081987637 hasRelatedWork W2341567294 @default.
• W2081987637 hasRelatedWork W2463309567 @default.
• W2081987637 hasRelatedWork W2755604283 @default.

• next